The Predictive Value of the Modified AFP Model for Liver Transplantation Outcomes in Multinodular Hepatocellular Carcinoma Patients

Jingrui Wang,Jiaqi Bao,Rui Wang,Jiachen Hong,Lincheng Zhang,Qingyang Que,Shengjun Xu,Yongfeng Wu,Qifan Zhan,Yuchen Liu,Jimin Liu,Shusen Zheng,Sunbin Ling,Xiao Xu

DOI: https://doi.org/10.1186/s12957-023-02994-y

2023-01-01

World Journal of Surgical Oncology

Abstract:Abstract Background There is a lack of studies focusing on the benefit of liver transplantation (LT) in hepatocellular carcinoma (HCC) patients with > 3 tumors. This study aims to establish a model to effectively predict overall survival in Chinese HCC patients with multiple tumors (> 3 tumors) who undergo LT. Methods This retrospective study included 434 HCC liver transplant recipients from the China Liver Transplant Registry. All HCC patients had more than 3 tumor nodules. Three selection criteria systems (i.e., AFP, Metroticket 2.0, and Up-to-7) were compared regarding the prediction of HCC recurrence. The modified AFP model was established by univariate and multivariate competing risk analyses. Results The AFP score 2 and the AFP score ≥ 3 groups had 5-year recurrence rates of 19.6% and 40.5% in our cohort. The prediction of HCC recurrence based on the AFP model was associated with a c-statistic of 0.606, which was superior to the Up-to-7 and Metroticket 2.0 models. AFP level > 1000 ng/mL, largest tumor size ≥ 8 cm, vascular invasion, and MELD score ≥ 15 were associated with overall survival. The 5-year survival rate in the modified AFP score 0 group was 71.7%. Conclusions The AFP model is superior in predicting tumor recurrence in HCC patients with > 3 tumors prior to LT. With the modified AFP model, patients likely to derive sufficient benefit from LT can be identified.